Donna Woods, MD
Psychiatry · Schaumburg, ILNPI 1215904529
Payments from drug & device makers
Across 51 payments — averaging $61.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$872
- Tris Pharma Inc$760
- Neos Therapeutics, LP$654
- Corium, LLC$450
- Supernus Pharmaceuticals, Inc.$382
What the payments were for
- Food & beverage$3,118100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 11 | $872 |
| Tris Pharma Inc | 8 | $760 |
| Neos Therapeutics, LP | 6 | $654 |
| Corium, LLC | 4 | $450 |
| Supernus Pharmaceuticals, Inc. | 22 | $382 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adzenys XR-ODT$654
- Dyanavel XR$608
- Quillichew ER$608
- Quillivant$608
- Azstarys$450
- JORNAY PM$354
- Jornay PM 20mg capsules (Bottle of 100)$116
How this compares
$3,118 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 12 | $5,401 |
| Oxcarbazepine | 15 | $2,942 |
| Methylphenidate ErMethylphenidate Hcl | 29 | $2,530 |
| Chlorpromazine Hcl | 13 | $2,181 |
| Olanzapine | 19 | $2,136 |
| Quetiapine Fumarate | 55 | $2,119 |
| Fluoxetine Hcl | 33 | $1,698 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $1,585 |
| Hydroxyzine Hcl | 18 | $1,250 |
| Aripiprazole | 33 | $1,238 |
| Bupropion XlBupropion Hcl | 37 | $947 |
| Guanfacine Hcl ErGuanfacine Hcl | 21 | $815 |
| Dexmethylphenidate Hcl | 20 | $704 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $611 |
| Escitalopram Oxalate | 24 | $608 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Schaumburg
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.